Thiopental

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Thiopental; Belgium: Pentothal; Bulgaria: Thiopental; Czech Republic: Thiopental; Denmark: Pentothal; Estonia: Thiopental; Finland: Pentothal; France: Pentothal; Germany: Thiopental, Thiopentone, Trapanal; Greece: Pentothal, Thiopental; Hungary: Thiopental; Ireland: Thiopental; Italy: Farmotal, Pentothal, Tiopen S; Latvia: Thiopental; Lithuania: Thiopental; Luxembourg: Nesdonal, Pentothal; Malta: Thiopental, Thiopentone; Netherlands: Pentothal; Poland: Thiopental; Portugal: Pentothal, Tiopental; Romania: Thiopental; Slovakia: Thiopental; Spain: Pentothal, Tiobarbital; Sweden: Pentothal; UK: Thiopental.

North America

Canada: Pentothal.

Latin America

Argentina: Bensulf, Hipnopento, Tiopental; Brazil: Thionembutal, Thiopentax; Mexico: Pentarim, Pentothal, Sodipental.

Asia

Japan: Ravonal.

Drug combinations

Chemistry

Thiopental Sodium: C~11~H~17~N~2~NaO~2~S. Mw: 264.32. (1) 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt, (±)-; (2) Sodium (±)-5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate. CAS-71-73-8; CAS-76-75-5 (thiopental).

Pharmacologic Category

General Anesthetics; Barbiturates. Barbiturate Anticonvulsant. (ATC-Code: N01AF03; N05CA19).

Mechanism of action

Short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity.

Therapeutic use

Induction of anesthesia. Adjunct for intubation in head injury patients. Control of convulsive states. Treatment of elevated intracranial pressure.

Pregnancy and lactiation implications

Unlabeled use

Contraindications

Hypersensitivity to thiopental, barbiturates, or any component of the formulation. Status asthmaticus. Severe cardiovascular disease. Porphyria (variegate or acute intermittent). Should not be administered by intra-arterial injection.

Warnings and precautions

May cause hypotension. Use with caution in hemodynamically unstable patients (hypotension or shock). May cause laryngospasm or bronchospasms (use with extreme caution in reactive airway diseases (asthma or COPD)). May cause paradoxical responses, including agitation and hyperactivity, particularly in acute pain and pediatric patients. May cause respiratory depression (use with caution in respiratory disease). Use with caution in Addison’s disease (may prolong or potentiate hypnotic effect). Use with caution in severe anemia (may prolong or potentiate hypnotic effect), in unstable aneurysms, in cardiovascular disease, in hepatic impairment, myasthenia gravis, myxedema, and renal impairment (may prolong or potentiate hypnotic effect), and in history of drug abuse (potential for drug dependency exists). Effects with other sedative drugs or ethanol may be potentiated. Use with caution in debilitated patients, and in excessively premedicated patients (may prolong or potentiate hypnotic effect). Do not administer in acute pain. Repeated dosing or continuous infusions may cause cumulative effects. Extravasation or intra-arterial injection causes necrosis due to pH of 10.6. Anticonvulsants should not be discontinued abruptly due to possibility of increasing seizure frequency.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart